eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2023
vol. 27
 
Share:
Share:
abstract:
Case report

FGFR2 point mutation in 2 cases of pleomorphic adenoma progressing to myoepithelial carcinoma

Julia Pikul
1
,
Anna Rzepakowska
1
,
Marcin Machnicki
2
,
Tomasz Stokłosa
2

  1. Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Warsaw, Poland
  2. Department of Tumour Biology and Genetics, Medical University of Warsaw, Poland
Contemp Oncol (Pozn) 2023; 27 (3): 211–216
Online publish date: 2023/12/09
View full text Get citation
 
PlumX metrics:
Introduction:
Salivary gland tumours are rare neoplasms. Pleomorphic adenoma (PA) is the most frequent benign lesion. Myoepithelial carcinoma (MECA) is rarely recognized malignancy, but the prognosis is unfavourable. The aim of this study was to identify genetic rearrangements that might be responsible for dynamic MECA progression in patients with primary radical PA excision.

Material and methods:
Next-generation sequencing (NGS) of 1500 gene coding sequences was performed in primary and recurrent tumour tissue collected from 2 patients, in whom PA was initially diagnosed and within one year multifocal MECA was detected. Formalin-fixed paraffin-embedded blocks with tumour tissues were subject to NGS analysis, involving small-scale mutations, as well as focal and chromosomal arm-level copy number changes.

Results:
This study showed mutations in the FGFR2 gene in PA and MECA tissues, obtained from both patients. One of them, pathogenic mutation p.Pro253Arg, was associated with sensitivity to registered drug inhibitors. Additionally, FGFR1, EGFR, and CDK4/CDK6 amplification, as well as CDKN2A/B deletion, were detected in one case. Furthermore, mutations in suppressor gene APC2 and PIK3C2A were detected, but only in MECA tissue. The analysis also identified the following chromosomal copy alterations: 4q12-q13.3, 9p21.3, 5q23.1-q34, del8p23.3-p12, and del13q21.31-q31.1.

Conclusions:
Rearrangement of the FGFR2 gene, identified in primary PA and MECA ex PA samples of both our patients, may be responsible for the malignant transformation and the disease progression. Further studies are encouraged to confirm the relevance of the findings. The therapy option with FGFR2 inhibitors may be considered in advanced or metastatic MECA ex PA with confirmed FGFR2 mutations.

keywords:

salivary gland, pleomorphic adenoma, myoepithelial carcinoma, malignant transformation, next-generation sequencing, FGFR2 mutation

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.